4 results
To further study the safety and effectiveness of the MitraClip system in the treatment of clinically significant functional mitral regurgitation in patients with New York Heart Association (NYHA) Functional Class III or Class IV chronic heart…
The primary objective of this study is to document the incidence of unanticipated device and procedure related adverse events intra-operatively and through one year follow-up.
The primary objective of the study is to compare the efficacy of brigatinib to that of crizotinib in ALK+ locally advanced or metastatic NSCLC patients naive to ALK inhibitors, as evidenced by PFS.The secondary objectives of the study are:1. To…
Primary:To evaluate the efficacy and safety of Ensartinib vs. crizotinib in patients with ALK-positive NSCLC that have received up to 1 prior chemotherapy regimen and no prior ALK tyrosine kinase inhibitor (TKI).Secondary:To obtain additional…